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Background: Knowledge of the characteristics of patients co-infected with tuberculosis (TB) and human
immunodeficiency virus (HIV) when TB treatment is initiated would allow clinicians to improve care and help
policy-makers develop relevant and realistic guidelines. The aim of this study was to describe socio-demographic,
clinical, and laboratory characteristics of TB/HIV co-infected patients starting inpatient TB treatment in Yaoundé,
Cameroon.
Methods: We conducted a retrospective cross-sectional study, collecting data from medical records of HIV-infected
patients with TB, aged 15 years old or more, hospitalized in the Infectious Diseases Unit of the Yaoundé Central
Hospital, Cameroon from January 1, 2006 to June 30, 2013.
Results: The mean age of 337 patients meeting study inclusion criteria was 39.3 years. More than half were female
(53.4%). Most (89.3%) resided in urban areas, 44.2% had a secondary education, and 46.0% were married. The majority
was receiving co-trimoxazole prophylaxis (79.5%), and two thirds were taking antiretroviral therapy (67.4%). The mean
duration of known HIV infection before TB treatment was 8.4 months. Most (88.1%) had newly diagnosed TB, rather
than relapsed disease. Smear-positive pulmonary TB was documented in a third, (35.3%). Laboratory data revealed a
median white blood cell count of 5,100 cells/mm3 (IQR 3,300-7,990 cells/mm3), a median hemoglobin level of 8 g/dl
(IQR 7–10 g/dl), and a median CD4 cell count of 102 cells/mm3 (IQR 33–178 cells/mm3). Sex differences in our study
included older age in the men (p < 0.001), more of whom were married (p < 0.001) and had achieved a higher level of
education (p = 0.042). Men had fewer diagnoses of smear-positive pulmonary TB (p = 0.020). They weighed more than
the women (p = 0.001) and had higher hemoglobin levels (p = 0.003).
Conclusions: Suboptimal adherence to WHO treatment recommendations in our Cameroonian study reinforces the
importance of prescribing co-trimoxazole in HIV infection and ART for all TB/HIV co-infected persons. We urge that
Ministries of Health continue implementing and disseminating guidelines for management of TB/HIV co-infected
patients, and we call for measures ensuring that healthcare facilities’ stocks of ART and co-trimoxazole are sufficient to
meet the need for both.
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The Word Health Organization (WHO) estimates that
the prevalence of tuberculosis (TB) in 2010 reached 12
million cases, corresponding to rates of 169 per 100,000
population worldwide and to 303 per 100,000 in Africa
[1]. The Centers for Disease Control (CDC) point out
that worldwide, approximately one third of persons are
infected with Mycobacterium tuberculosis [2] unders-
coring the enormity of the global burden of TB. In most
persons, TB infection remains latent and clinically quies-
cent; however in others, TB progresses and leads to ac-
tive, infectious TB illness. The millennium development
goals for global TB control are to halt and then, to begin
reversing the increasing incidence of TB in order to
halve the 1990 prevalence and death rates by 2015 [3].
Cameroon most recently recorded a total of 26,110 cases
of TB nationally, with 15,080 new smear-positive cases,
corresponding to rates of 124 and 73 per 100,000
population respectively [4]. The rate of successful tuber-
culosis treatment has been progressively increasing in
Cameroon, from 72% in 2003 to 80% in 2013 [4].
People living with human immunodeficiency virus
(HIV) are much more likely to develop active TB than
those who are HIV-negative [1]. The greatest burden of
combined TB and HIV infections is seen in sub-Saharan
Africa, where the extent of the problem is tragically,
inversely proportional to the paucity of resources available
for effective control and treatment. Although sub-Saharan
Africa has borne the brunt of TB/HIV co-infection and its
consequences to date, other parts of the world are increa-
singly struggling with increasing TB and HIV-related mor-
bidity and mortality as well. HIV infection is frequent
among patients with active TB in Cameroon and dispro-
portionately affects women [5,6]. Studies in Cameroon in-
dicate that the HIV infection rate among TB patients has
been rapidly increasing, from 16.6% in 1997 [7] to 51.6%
in 2012 [8]. Recent estimates from CDC taking into ac-
count the fact that TB detection and reporting data from
sub-Saharan Africa are often incomplete (underestimates),
project that there will be 19,000 new HIV-positive TB pa-
tients in Cameroon alone in 2013 [2]. Reports from the
Cameroonian Ministry of Public Health reveal that in
2013, 82% of patients known to have TB had also been
tested for HIV; of those tested, 38% were HIV-infected;
and of those co-infected with TB and HIV, 65% were being
treated concurrently for both TB and HIV [4].
Despite the encouraging mortality figures from TB oc-
curring in the setting of HIV, better knowledge and un-
derstanding of the presentation of TB/HIV co-infected
patients at the time of TB diagnosis would allow cli-
nicians to improve their care and would help policy
makers in developing targeted guidelines. The aim of
this cross-sectional study was thus to describe socio-
demographic, clinical, and laboratory characteristics ofTB/HIV co-infected patients at the time of TB diagnosis
and treatment initiation in Yaoundé, Cameroon.
Methods
Study design and setting
The study was approved by Review Board of the Faculty
of Medicine and Biomedical Sciences, University of
Yaoundé 1. Written informed consent was obtained
from the patient for the inclusion in this study. The
retrospective, cross-sectional study focused on baseline
characteristics of TB/HIV co-infected patients at the time
when anti-tuberculous treatment was initiated. Data was
collected from medical records in the Infectious Disease
Unit (IDU) of the Yaoundé Central Hospital (YCH),
Cameroon. The YCH houses an accredited treatment
center, which is a major treatment center for HIV-infected
patients in Cameroon. IDU of YCH manages 2% of all the
TB cases in Cameroon annually [9]. All diagnosed TB
cases are prescribed standard TB regimens and followed-
up, with outcomes reported according to national TB con-
trol guidelines [9].
Study population
TB cases were identified in the Tuberculosis Reporting
Register of the IDU of the YCH, which is the official sys-
tem for mandatory reporting of TB cases in the hospital.
TB reporting is mandatory nationwide for new cases,
relapses, and reentries after treatment dropout. All pa-
tients entered in the Register from January 1, 2006
to June 30, 2013 were evaluated for inclusion in the
study. We included HIV-infected patients with TB, aged
15 years old or older.
Data collection
We collected data from the TB registry of the IDU-YCH,
from the hospitalization registry of the IDU, from medi-
cal records of hospitalized TB/HIV co-infected patients,
and from the TB yellow cards of TB/HIV co-infected pa-
tients. A TB yellow card is a document on A4 format
paper [9] used in anti-tuberculosis treatment. It contains
the following information: the patient’s name, sex, age,
addresses, TB localization, type of TB at treatment initia-
tion, HIV status, and a calendar with check boxes for
each day of taking anti-TB drugs.
We collected socio-demographic data including: age,
sex, marital status, highest level of education, and resi-
dence. We also collected relevant clinical data. Patients
were classified by the physician-in-charge of the CDT ac-
cording to features of their clinical TB presentation,
using the WHO standard international definitions [1] as
one of the following: smear-positive pulmonary TB
(Acid-fast bacilli [AFB] originally found in at least two
sputum specimens), smear-negative pulmonary TB (per-
sistence of negative result of three sputum examinations
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patient with clinical and radiographic signs suggesting
pulmonary TB without other obvious cause), and extra-
pulmonary TB (a patient in whom TB was found in
organs other than the lungs [e.g. pleura, lymph nodes,
abdomen, genitourinary tract, skin, joints and bones,
meninges]). Extra-pulmonary TB lies for the most part
on the clinical decision based on suggestive clinical
signs and evidence of a predominantly lymphocytic
exudate as in the case of peritoneal TB with ascites or
granulomatous lesions on histopathological examination
of lymph nodes or other pieces of tissue obtained by
biopsy. We defined as “mixed form” all presentations in
which a patient had evidence of both pulmonary TB
and extra-pulmonary TB. The WHO standard inter-
national definitions [1] were further used to categorize
each person’s TB status at diagnosis: as either a new case
or a retreatment case. Other clinical variables recorded
from patients’ medical records included body weight;
the presence of other AIDS-related opportunistic infec-
tions from clinical stages 2 to 4 as defined by WHO
[10]; occurrence of non-TB and non-HIV related co-
morbidities the most frequent being non-AIDS defining
bacterial infections, malaria, diabetes, and hypertension;
information on treatment outcomes; and whether or not
the patient received Co-trimoxazole Prophylactic Therapy
(CPT) and Anti-Retroviral Therapy (ART). LaboratoryExcluded: 
HIV negative or
no HIV test result 
n = 279
Review of TB regist
from 2006 to 2013












Figure 1 Flowchart for TB/HIV inpatients in the infectious diseases undata included CD4 cell counts, hemoglobin level, and
white blood cell counts.
Data analysis
Data was coded, entered, and analysed using the Statistical
Package for Social Science (SPSS) version 20.0 for Windows
(IBM Corp. Released 2011. IBM SPSS Statistics for
Windows, Version 20.0. Armonk, NY: IBM Corp.). We
described continuous variables using means (standard
deviation [SD]) or median (interquartile range [IQR]), and
categorical variables using their frequencies (percentages).
The chi-square test or Fisher’s exact test when ap-
propriate, were used to compare categorical variables,
Student’s t-test was used to compare means, and the
Mann–Whitney U test was used to compare medians. All
statistical tests were performed using two-sided tests at a
0.05 level of significance. Multiple imputation method was
used to handle missing data, by creating a new data set,
which was the average of five data sets of imputed values
imputation [11,12]. This dataset has been used to compare
body weight, CD4 count, hemoglobin level, and white
blood cells count regarding sex and TB status at diagnosis.
Results
Figure 1 presents the flowchart of our study population.
Of the 337 patient charts meeting inclusion criteria, we
had missing values for weight in 36 records (10.7% ofry 
s old
Excluded: 
• No outcomes documented (n = 14)
• Died prior to or at TB treatment 
initiation (n = 13)
• Incomplete file information (at 
least 35%) (n = 38)
-
it of the Yaoundé Central Hospital (2006–2013).
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white blood cell counts in 21 records (6.2% of total), and
for hemoglobin levels in 21 records (6.2% of total).
Socio-demographic, clinical, and laboratory profile of the
study population
Table 1 presents our study cohort’s (n = 337) socio-
demographic, clinical, and laboratory characteristics. The
mean age of our patients was 39.3 years (SD 10.3) and the
median was 38 years (IQR 32–46). There were slightly
more women than men as 53.4% (n =180) were female.
The greatest number had attained a secondary level of
education (44.2%, n = 149). The majority of patients were
married (46.0%, n = 155), closely followed by single status
(44.8%, n = 151). The median duration of known HIV in-
fection at the time of TB diagnosis was 0.97 (IQR 0.13-5.7)
months and the mean was 8.2 (19.0) months. Patients’
mean body weight was 52.3 kg (SD 10.3). Most cases of tu-
berculosis represented new disease (88.1%, n = 297). Most
of patients – over one third - had pulmonary TB alone
(37.1%, n = 125), closely followed by extra-pulmonary
disease (n = 119, 35.3%). Figure 2 details the distribution of
the forms of extra-pulmonary tuberculosis in our patients.
Lymph nodes (tuberculous lymphadenitis) were the most
common extra-pulmonary site, representing a third of all
extra-pulmonary tuberculosis (31.2%, n = 43) in our co-
hort. Other AIDS-related opportunistic infections and
other (non-AIDS and non-TB) comorbidities were present
in 53 (15.7%) and 40 (11.9%) patients respectively. Regar-
ding HIV treatment, CPT and ART had been prescribed to
268 (79.5%) and 227 (67.4%) of the patients. The median
CD4 count, white blood cells count, and hemoglobin
level were 102 cell/mm3 (IQR 33–178), 5,100 cell/mm3
(3,300-7,990), and 8 g/dl (7–10) respectively.
Comparison regarding sex and TB status at diagnosis
Table 1 includes a comparison of females and males in
our study. Regarding socio-demographic characteristics,
men were older than women (p < 0.001), more were mar-
ried (p < 0.001) and had achieved a higher level of educa-
tion (p = 0.042). As far as their clinical presentation, males
had more smear-positive (PTB+) and smear negative
(PTB-) pulmonary TB, less extra-pulmonary TB, and less
mixed forms of TB (p = 0.020). Men also weighed more
than women (p = 0.001). On laboratory evaluation, men
had higher hemoglobin levels (p = 0.003). The patients
with recurrent tuberculosis and classified as TB retreat-
ment cases were older than patients with a new diagnosis
of TB (p = 0.042) and had longer duration of known HIV
infection (p = 0.004) (Table 2).
Discussion
The most frequent clinical presentation of patients diag-
nosed with tuberculosis in the setting of HIV co-infection was that of smear-positive pulmonary TB, just as
has been observed from reports of TB and HIV co-
infection from other geographic areas outside of sub-
Saharan Africa [13]. The majority of our cases represented
newly diagnosed TB and presented in an advanced state
of immune deficiency, with low CD4 T-cell counts. We
found low frequencies of AIDS-related opportunistic in-
fections and of other (non-AIDS and non-TB) comor-
bidities. The extent of CPT and ART in our study is
consistent with data recently reviewed and reported by
the Centers for Disease Control [2] and fails to achieve
the recommended treatment goals of the WHO and the
Cameroon’s Ministry of Public Health [9].
Socio-demographic profile
Currently, there is no conclusive evidence of sex-based
differences in the occurrence of TB and HIV co-
infection in developing countries [6,14-17]. Our study
also had a slight preponderance of co-infected women
(53.4%) as compared to men. The apparent sex-based
difference is probably related to the high incidence of
HIV infection among females in sub-Saharan Africa in
general [17,18] and Cameroon in particular [5,18].
Women, who have a higher susceptibility to HIV infec-
tion [19-21], are usually exposed to sexual activity earlier
than men in francophone sub-Saharan Africa, and par-
ticularly in Cameroon [22].
In terms of age distribution, the median age was
38 years (IQR 32–46 years) and the mean was 39.3
(SD10.3 years). This is consistent with the findings of
other studies [14,23-27]. The TB/HIV co-infection age
distribution likely reflects the age-specific prevalence of
HIV in the community. This in turn relates to patients’
being in a sexually active age group and encountering
sexual partners in whom both TB and HIV are prevalent.
In our study, the men with TB and HIV were signifi-
cantly older than the women. In Cameroon, HIV pre-
valence is higher in young females compared to young
males [5]. Furthermore, the age group most affected by
HIV infection in women is 35–39 years (HIV prevalence
10.0%) and in men is 45–49 years (HIV prevalence 6.3%)
[5]. Age was also greater among the patients undergoing
retreatment of TB as compared to new TB cases. This
result is not surprising and is logical, as the passage of
time and ageing increase the risk of TB relapse.
In our population, a secondary level of education was
the most representative with 44.2% of patients, although
men completed a higher level of education than did
women. Our results are consistent with others studies
[5,16,27]. Findings from a nationwide survey in Cameroon
[5] revealed that HIV prevalence is highest among those
with primary or secondary/1st cycle education; the same
would be thus expected for those with HIV complicated
by the emergence of TB.
Table 1 Socio-demographic, clinical, and laboratory profiles of TB/HIV infected patients in Yaoundé Central Hospital
(2006–2013), overall and by sex
Male n = 157 Female n = 180 p Total N = 337
Socio-demographic profile
Mean age, years 41.8 (9.2) 37.1 (10.7) < .0001 39.3 (10.3)
Level of education
• No formal 16 (10.2) 32 (17.8) .042 48 (14.2)
• Primary 26 (16.6) 22 (12.2) 48 (14.2)
• Secondary 64 (40.8) 85 (47.2) 149 (44.2)
• University 51 (32.5) 41 (22.8) 92 (27.3)
Residence
• Rural 22 (14.0) 14 (7.8) .065 36 (10.7)
• Urban 135 (86.0) 166 (92.2) 301 (89.3)
Matrimonial status
• Alone (single/divorced/widower) 59 (37.6) 123 (68.3) < .0001 182 (54.0)
• Married 98 (62.4) 57 (31.7) 155 (46.0)
Clinical profile
Clinical presentation of TB
• PTB+ only 48 (30.6) 77 (42.8) .020 125 (37.1)
• PTB- only 32 (20.4) 43 (23.9) 75 (22.3)
• EPTB only 65 (41.4) 54 (30.0) 119 (35.3)
• EPTB + PTB 12 (7.6) 6 (3.3) 18 (5.3)
TB status at diagnosis
• New 135 (86.0) 162 (90.0) .256 297 (88.1)
• Retreatment 22 (14.0) 18 (10.0) 40 (11.9)
Mean duration of known HIV infected, months 10.3 (22.1) 6.5 (15.8) .076 8.2 (19.0)
Mean body weight, kg¥ 55.4 (9.7)α 51.5 (10.4)β .001 52.3 (10.3)
55.6 (9.9) 51.3 (10.4) .001 53.3 (10.4)
Presence of another (excluding TB) AIDS
opportunist infections (stage 2 – 4 of WHO
classification of HIV infection)
28 (17.8) 25 (13.96) .321 53 (15.7)
Presence of other comorbidities, non-AIDS
and non-TB
18 (11.5) 22 (12.2) .830 40 (11.9)
Co-trimoxazole prophylactic therapy 125 (79.6) 143 (79.4) .969 268 (79.5)
Antiretroviral therapy 112 (71.3) 115 (63.9) .146 227 (67.4)
Biological profile
Median CD4 count, cell/mm3 ¥ 74 (27–193)μ 115 (42–172)£ .363 102 (33–178)
75 (28–193) 116 (43–174) .681 103 (34–181)
Median white blood cell count, cell/mm3 ¥ 5,115 (3,300-7,800)π 5,100 (3,400-8,000)ε .871 5,100 (3,300-7,990)
5,100 (3250–7800) 5,200 (3,300-8,200) .682 5,130 (3,300-8,000)
Median hemoglobin level, g/dl¥ 9 (7–10)π 8 (6–10)ε .003 8 (7–10)
9 (7–10) 8 (6–10) .002 8 (7–10)
Data are mean (standard deviation), n (%) and median (interquartile range).
Missing data: α20, β16, μ10, £18, π7, and ε11.
PTB+ and PTB-: smear –positive and –negative pulmonary TB.
EPTB: Extra pulmonary TB.
¥The row under this variable presents sensitivity analysis after multiple imputation of missing data.
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Figure 2 Frequency of clinical forms of extra pulmonary TB among TB/HIV infected patients in Yaoundé Central Hospital from 2006 to
2013 (n = 138). Data are: clinical form; n; proportion (%).
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resided in an urban area. Studies, particularly those in
sub-Saharan African countries, have shown that the
number TB/HIV co-infected cases is higher in urban
than rural areas [8]. It is also important to note however,
that our study was conducted in a tertiary-care hospital
located in an urban area. The Yaoundé area’s inhabitants
are typical of the urban population of Cameroon.
Almost half of the patients were married (46.0%). In
our study, more men than women were married. There
are several possible explanations. A man may be more
likely to abandon his wife when she becomes ill (especially
in case of HIV infection) and then remarry; also, polygamy
is authorized in Cameroon, so if a man is abandoned by
one of his wives, he may have others wives and thus stay
married. Finally, because of cultural, economic, societal,
and religious constraints, women are overall more likely
to remain in a marriage than men.
Clinical profile
In our study, the most frequent clinical presentation of
tuberculosis was smear-positive pulmonary disease alone(37.1%), followed by extra-pulmonary TB (35.3%). There
have been conflicting reports on the frequency of the vari-
ous clinical presentations of TB in TB/HIV co-infected pa-
tients. Several studies have shown a higher occurrence of
smear-negative pulmonary TB [16,26,28,29], while others
have shown a high occurrence of extra-pulmonary TB
[30]. Our findings are similar to those of Pefura et al.
in Yaoundé, Cameroon [8] and to other studies from
Malaysia and Brazil [23,24]. Those reports differ from
other published data reporting a greater proportion of
smear-negative pulmonary TB and extra-pulmonary TB
diagnoses in TB/HIV co-infected patients, particularly in a
background of advanced immune deficiency (AIDS) where
TB tends to present atypically and to more frequently dis-
seminate outside the lung [31]. We acknowledge that one
explanation for our results - obtained from a hospital in-
patient setting - could be the fact that patients with
smear-positive pulmonary TB are more likely than smear
negative patients to be hospitalized in order to prevent
transmission of the bacilli to others.
Of the 121 (35.9%) patients with isolated extra-
pulmonary TB and 16 (4.7%) with the mixed clinical
Table 2 Comparison of socio-demographic, clinical, and
laboratory profiles between patients with a new
diagnosis of TB and those with retreatment TB in
Yaoundé Central Hospital (2006–2013)
Retreatment






Male 22 (55.0) 135 (45.5) .256
Mean age, years 42.4 (8.6) 38.9 (10.4) .042
Level of education
• No formal 5 (12.5) 43 (14.5) .956
• Primary 5 (12.5) 43 (14.5)
• Secondary 18 (45.0) 131 (44.1)
• University 12 (30.0) 80 (26.9)
Residence
• Rural 4 (10.0) 32 (10.8) 1.0




17 (42.5) 165 (55.6) .120




• PTB+ only 16 (40.0) 109 (36.7) .975
• PTB- only 8 (20.0) 65 (22.6)
• EPTB only 14 (35.0) 105 (35.4)
• EPTB + PTB 2 (5.0) 16 (5.4)
Mean duration
of known HIV infected,
months
22.9 (33.6) 6.3 (15.2) .004
Mean body weight, kg¥ 53.2 (9.5)α 53.2 (10.4)β .996




infections (stage 2 – 4
of WHO classification
of HIV infection)




8 (20.0) 32 (10.8) .114
Co-trimoxazole
prophylactic therapy
32 (80.0) 236 (79.8) .937
Antiretroviral therapy 32 (80.0) 195 (65.7) .069
Table 2 Comparison of socio-demographic, clinical, and
laboratory profiles between patients with a new
diagnosis of TB and those with retreatment TB in




74 (19–169) 102 (34–181)£ .298




5,750 (3,825-8,045) 5,000 (3,290-7,900)ε .615
5,750 (3,825-8,045) 5,100 (3,260-8,000) .538
Median hemoglobin
level, g/dl¥
9 (7–10) 8 (7–10)ε .846
9 (7–10) 8 (7–10) .802
Data are mean (standard deviation), n (%) and median (interquartile range).
Missing data:α2, β34, £28, and ε18.
PTB+ and PTB-: smear -positive and –negative pulmonary TB.
EPTB: Extra pulmonary TB.
¥The row under this variable presents sensitivity analysis after multiple
imputation of missing data.
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presentation (31.2%). Our findings are in agreement with
others in developing countries [30,32-34]. Indeed, this
reflects the profound host immune suppression induced
by HIV infection, which facilitates the dissemination of
Mycobacterium tuberculosis out of the lungs, via lym-
phangitic spread [35] and causes the reactivation of
infection in extra-pulmonary organs [36]. However, the
relative diagnostic ease with which lymph node TB is
detected and diagnosed as compared to other forms of
extra-pulmonary TB in resource-limited settings such as
Cameroon, may be considered as a partial explanation
for the higher percentage of lymph node TB.
The median duration of known HIV infection when
anti-tuberculous treatment was initiated was 0.97 (IQR
0.13-5.7) months. Apart from TB, 15.7% of patients had
an additional AIDS-related opportunistic disease and
11.9% had other co-morbid conditions, which were nei-
ther TB nor AIDS-related opportunistic diseases or
infections. These findings are congruent with those in
Malaysia [23] and likely reflect the fact that the occur-
rence of tuberculosis is the first manifestation of AIDS
in most patients.
The median weight of our patients was 53 kg. Very
few studies have looked at this variable and our study
shows similar findings to the published literature
[23,26]. Unfortunately, we could not obtain data as body
mass index. Weight loss is common in the setting of
both TB and HIV infection [37]. In our study, the men’s
body mass was greater than that of women, which is
expected.
At TB treatment initiation, the majority of patients
(79.5%) were receiving CPT. This is higher than the
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Cameroon, CPT is indicated in all cases of TB/HIV co-
infection both in adults and children, irrespective of the
CD4 cell count level and WHO clinical stage [9]. This
implies all the patients in our cohort were eligible for
CPT but the complete coverage (100%) was not attained.
The mindset of some clinicians who place more em-
phasis on prescribing ART, regarded as lifesaving, while
unfortunately neglecting CPT might be an explanation
for this finding. It may also be possible that busy CDT
staff neglected to consistently document adherence to
CPT prescribing in the medical record. The occurrence
of insufficient medication supplies and the inadequacy of
CPT stocks at the CDT requiring patients to obtain
medication elsewhere on their own are also possible
explanations.
More than half of the patients (67.4%) had started
ART, yet the frequency of ART coverage among TB/HIV
co-infected patients remained less than the 80% co-
verage target set by the Ministry of Public Health in
Cameroon [9]. Despite recommendations of WHO (all
HIV-infected patients must be on ART), some clinicians
remain reluctant to prescribe ART to their HIV-infected
TB patients, due to concerns about overlapping toxi-
cities, pill burden, and immune reconstitution inflam-
matory syndrome [39]. Nonetheless, the extent of ART
coverage for TB/HIV co-infected patients in studies car-
ried out in North-West region in Cameroon [38], in
Southwest Ethiopia [26], and in Trinidad and Tobago
[25] was less than what we found. One important factor
underlying the difference in the extent of coverage is the
fact that all our patients were hospitalized, and so, it was
easier to administer ART to patients and to and ensure
follow-up.
Laboratory profile
In an immunocompetent host, infection causes elevation
of white blood cell counts. In TB/HIV co-infected pa-
tients however, as infection progresses, there is depletion
of neutrophils and monocytes by Mycobacterium tuber-
culosis and lymphocytes (CD4 especially) by HIV [40].
In this study, total white blood cell counts were docu-
mented prior to TB treatment initiation; the median
white blood cell count was 5,100 cells/mm3 (normal
range). A study carried out in Malaysia by Ismail et al.
reports similar findings [23].
The median hemoglobin level in our patients was 8 g/dl,
comparable to what Ismail et al. found in their population
[23]. In TB patients, anemia may occur as a result of sup-
pression of erythropoiesis by inflammatory mediators [40].
Anemia in HIV-positive patients has an extensive diffe-
rential diagnosis, which includes lympho-proliferative dis-
orders, abnormal iron metabolism, hemolysis, and bone
marrow suppression (especially with zidovudine) [41,42].Our study found a difference between males and females
regarding hemoglobin concentration, as expected. It is
well established that the hemoglobin concentration is
physiologically lower in women [43].
Our study shows that, at the time of inpatient TB
treatment initiation, most patients were at an advanced
immune deficiency state as the median CD4 T-cell count
was 102 cells/mm3. This finding is similar to other stu-
dies in developing countries [16,23,25,27,30]. HIV im-
pairs the host’s immune system [44], setting the stage for
the emergence of opportunistic infections like TB, as in
our study subjects, and further depletion of CD4 cells
[45] ultimately leading to illness requiring medical inter-
vention. Altogether, the synergism between HIV and TB
is a reflected in the level of CD4 cell counts measured in
our patients [45,46].
Limitations
Our study captured patients undergoing treatment for tu-
berculosis over a 90-month period, from January 1, 2006
through June 30, 2013. Starting in 2012, guidelines issued
by the Cameroonian Ministry of Public Health for prescri-
bing ARTchanged. Prior to 2012, it was recommended that
ART therapy in the setting of HIV be started when the
CD4 cell count was less than 200 cells/mm3; the 2012 revi-
sion instead advised starting ART once the CD4 cell count
dropped to 350 cells/mm3. This likely lead to more of our
patients being started on ART later in the study period; tu-
berculosis guidelines however, remained unchanged for the
entire period of our study. Some data for body weight,
hemoglobin level, white blood cell count, and CD4 count
were missing. In those four categories, the range of missing
data was between 6.2 and 10.7%. The reasons for the miss-
ing data included failure to enter information in the medi-
cal treatment records, and the inability for some patients to
pay for laboratory evaluations, which were thus not ob-
tained. Whatever the underlying cause, the missing data
underscore the challenges of conducting “real-life” clinical
research in resource-limited settings, like Cameroon and
other sub-Saharan countries. Aggregate data derived from
laboratory testing should be interpreted cautiously as
technological advances in the measurement of hemato-
logical and immunological parameters over the 8 years of
our study, with concurrent changes in methodologies and
in laboratory equipment preclude making precise compari-
sons over time. In addition, as some patients had their la-
boratory examinations performed in settings other than the
YCH, including in private laboratories, we could not retro-
spectively ascertain which autoanalyzers and laboratory
equipment were used to perform those exams.
Conclusions
In a population of hospitalized Cameroonian patients
beginning TB treatment in the setting of HIV co-
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ried, lived in urban areas, and had attained a secondary
level of education. Women were younger and fewer were
married, as compared to the men. The most common
TB presentation was smear-positive pulmonary TB,
closely followed by extra-pulmonary TB. Most of our TB
cases were new cases; there were few other AIDS-related
opportunistic diseases and few non-AIDS related co-
morbidities. Most patients were at an advanced stage of
immunosuppression. Adherence to the WHO and the
Cameroonian Ministry of Public Health recommenda-
tions of TB and HIV co-infection was suboptimal and
needs to be improved. In the light of this study, we urge
clinicians to prescribe ART for all persons co-infected
with TB and HIV and to also treat all HIV infected
individuals with CPT, as per the most recently issued
treatment guidelines. We further recommend that the
Ministry of Health continue promoting and implement-
ing guidelines for the best management of HIV-infected
patients and especially for those with TB complicating
HIV, by targeting all health care personnel in a con-
certed educational outreach.
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